Altimmune, Inc. (ALT)

Altimmune Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.41	0.43	-0.07	4.41	8.19	5.8
Revenue Growth (YoY)	-	-	-	-46.12%	41.09%	-43.85%
Gross Profit	0.41	0.43	-0.07	4.41	8.19	5.8
Selling, General & Admin	18.92	18.14	17.13	15.41	13.21	8.5
Research & Development	70.04	65.8	70.54	74.54	49.77	17.77
Other Operating Expenses	12.42	12.42	0	11.37	0	1
Operating Expenses	101.37	96.36	87.67	101.32	62.98	27.27
Operating Income	-100.96	-95.93	-87.74	-96.91	-54.8	-21.46
Interest Expense / Income	0.03	0.04	0.01	0.01	0.01	0
Other Expense / Income	-8.23	-7.52	-2.84	0.17	-0.35	-0.89
Pretax Income	-92.77	-88.45	-84.91	-97.09	-54.46	-20.58
Income Tax	0	0	-0.2	0	-5.42	-0.06
Net Income	-92.77	-88.45	-84.71	-97.09	-49.04	-20.52
Preferred Dividends	0	0	0	0	0	0.45
Net Income Common	-92.77	-88.45	-84.71	-97.09	-49.04	-20.97
Shares Outstanding (Basic)	71	53	47	41	26	13
Shares Outstanding (Diluted)	71	53	47	41	26	13
Shares Change	41.25%	13.47%	13.67%	61.03%	95.33%	368.35%
EPS (Basic)	-1.61	-1.66	-1.81	-2.35	-1.91	-1.60
EPS (Diluted)	-1.61	-1.66	-1.81	-2.35	-1.91	-1.60
Free Cash Flow	-72.76	-75.86	-62.71	-90.36	-34.51	-9.6
Free Cash Flow Per Share	-1.03	-1.43	-1.34	-2.19	-1.35	-0.73
Gross Margin	100.00%	100.00%	-	100.00%	100.00%	100.00%
Operating Margin	-24625.37%	-22518.54%	-	-2197.60%	-669.50%	-370.00%
Profit Margin	-22626.10%	-20762.21%	-	-2201.59%	-599.20%	-361.52%
Free Cash Flow Margin	-17745.37%	-17806.81%	-	-2048.87%	-421.62%	-165.53%
EBITDA	-91.79	-87.94	-84.41	-96.53	-54.02	-20.19
EBITDA Margin	-22388.54%	-20642.02%	-	-2188.98%	-660.02%	-348.00%
Depreciation & Amortization	0.94	0.48	0.49	0.55	0.43	0.39
EBIT	-92.73	-88.41	-84.9	-97.09	-54.45	-20.58
EBIT Margin	-22617.80%	-20753.99%	-	-2201.47%	-665.26%	-354.68%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).